New NASH drug candidate BAR502 enters first human safety trial
NCT ID NCT06705998
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This is the first time BAR502, an experimental drug for NASH (a serious liver condition), is being tested in humans. The study involves 52 healthy adults to check the drug's safety, tolerability, and how the body processes it. Participants receive either a single dose or multiple doses of BAR502 or a placebo. This early-stage trial does not aim to treat NASH but to gather essential safety data for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BAR502 (oral tablet)
What this could lead to
If successful, this early study could pave the way for future trials of BAR502 as a potential treatment for NASH (a liver disease).
What could go wrong
This is a very early Phase 1 trial in only 52 healthy people, not patients. It primarily checks safety, not whether the drug works for NASH. Many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CROSS Research S.A. Phase I Unit
RECRUITINGArzo, CH-6864, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••